Fotios Loupakis

23.4k citations

315 papers · 11.6k indexed · 7 hit papers · h-index 51

Impact in

Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 263
- Colorectal Cancer Treatments and Studies 238
- Cancer Treatment and Pharmacology 84
Hepatology 62
- Hepatocellular Carcinoma Treatment and Prognosis 61

Co-authors: Alfredo Falcone Federica Di Nicolantonio Alberto Bardelli Emily Crowley Chiara Cremolini Gianluca Masi Lisa Salvatore Giuseppe Tonini
Journals: Journal of Clinical Oncology (92 papers)Annals of Oncology (41 papers)The Pharmacogenomics Journal (14 papers)Clinical Colorectal Cancer (10 papers)European Journal of Cancer (10 papers)
Partner nations: Italy United States Germany

In The Last Decade

Fotios Loupakis

302 papers receiving 11.5k citations

Hit Papers

7 papers align trajectories log scale

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer 2023 · 96 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Communications
2021 Journal of Clinical Oncology
2019 Nature Genetics
2015 JNCI Journal of the National Cancer Institute
2015 The Lancet Oncology
2014 New England Journal of Medicine
2013 Nature Reviews Clinical Oncology

Peers

Countries citing papers authored by Fotios Loupakis

Since Specialization

Citations

This map shows the geographic impact of Fotios Loupakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fotios Loupakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fotios Loupakis more than expected).

Fields of papers citing papers by Fotios Loupakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fotios Loupakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fotios Loupakis. The network helps show where Fotios Loupakis may publish in the future.

Co-authors

The 25 scholars most cited alongside Fotios Loupakis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fotios Loupakis Line = papers co-authored together Fotios Loupakis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study Journal of Clinical Oncology ·Josep Tabernero, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik-Tobias Arkenau, Pilar García‐Alfonso, Élena Elez, Ashwin Gollerkeri, Kati Maharry, Janna Christy‐Bittel, Scott Kopetz Hit paper breakdown →	2021	331
2	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC Molecular Cancer Therapeutics ·Hiroyuki Arai, Shu Cao, Francesca Battaglin, Jingyuan Wang, Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz‐Josef Lenz	2021	0
3	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study Cancers ·Letizia Procaccio, Francesca Bergamo, Francesca Daniel, Cosimo Rasola, Giada Munari, Paola Biason, Stefania Crucitta, Giulia Barsotti, Giulia Zanella, Valentina Angerilli, Cristina Magro, Silvia Paccagnella, Veronica Di Antonio, Fotios Loupakis, Romano Danesi, Vittorina Zagonel, Marzia Del Re, Sara Lonardi, Matteo Fassan	2021	12
4	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer Journal for ImmunoTherapy of Cancer ·Hiroyuki Arai, Yi Xiao, Fotios Loupakis, Natsuko Kawanishi, Jingyuan Wang, Francesca Battaglin, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Daniel J. Weisenberger, Gangning Liang, Chiara Cremolini, Alfredo Falcone, Joshua Millstein, Heinz‐Josef Lenz	2020	27
5	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib The Pharmacogenomics Journal ·Marta Schirripa, Beatrice Borelli, Romina D’Aurizio, Simone Lubrano, Chiara Cremolini, Gemma Zucchelli, Carlotta Antoniotti, Federica Marmorino, Alessandra Anna Prete, Sabina Murgioni, Francesca Bergamo, Vittorina Zagonel, Andrea Tuccoli, Andrea Marranci, Milena Rizzo, Lorena Tedeschi, Letizia Magnoni, Alfredo Falcone, Fotios Loupakis, Laura Poliseno	2019	5
6	Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) Annals of Oncology ·Guillem Argilés, N. Mulet Margalef, Manuel Valladares‐Ayerbes, J. Vieitez de Prado, Cristina Grávalos, Pilar Alfonso, Catarina Santos, M. Tobeña, Javier Sastre, Manuel Benavides, T. Cano, Fotios Loupakis, Mercedes Rodríguez Garrote, Fernando Rivera, Richard M. Goldberg, Alfredo Falcone, Jaafar Bennouna, Fortunato Ciardiello, Josep Tabernero, Enrique Aranda	2019	15
7	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study Clinical Colorectal Cancer ·Marta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, Mario Scartozzi, Sara Lonardi, Laura Rumano', Francesca Bergamo, Silvia Stragliotto, Sabina Murgioni, Giulia Alberti, Mario Domenico Rizzato, Alessandra Anna Prete, Marco Puzzoni, Valeria Pusceddu, Pina Ziranu, Fabiana Pani, Stefano Mariotti, Vittorina Zagonel, Fabio Monzani, Fotios Loupakis	2018	11
8	The role of tumor angiogenesis as a therapeutic target in colorectal cancer Expert Review of Anticancer Therapy ·Francesca Battaglin, Alberto Puccini, Rossana Intini, Marta Schirripa, Alessandra Ferro, Francesca Bergamo, Sara Lonardi, Vittorina Zagonel, Heinz‐Josef Lenz, Fotios Loupakis	2018	44
9	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab Clinical Cancer Research ·Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Dongyun Yang, Yu Sunakawa, Satoshi Matsusaka, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Diana L. Hanna, Shivani Soni, Alberto Puccini, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz‐Josef Lenz	2017	21
10	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients Clinical Cancer Research ·Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Alì, Daniele Rossini, Valeria Merz, Raffaela Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, Davide Melisi	2017	41
11	Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO Annals of Oncology ·Daniele Santini, Chiara Cremolini, Lisa Salvatore, Sara Lonardi, Emanuela Dell’Aquila, Monica Cattaneo, Fotios Loupakis, Daniele Rossini, Bruno Vincenzi, S. Ziampiri, Vanessa Buoro, Emiliano Tamburini, Debora Basile, Domenico Corsi, Iacopo Fioroni, Gianluca Masi, Beatrice Borelli, Marzia Del Re, Giuseppe Tonini, Alfredo Falcone	2017	0
12	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy Clinical Cancer Research ·Satoshi Matsusaka, Diana L. Hanna, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Satoshi Okazaki, Martin D. Berger, Yuji Miyamato, Anish Parekh, Sebastian Stintzing, Fotios Loupakis, Heinz‐Josef Lenz	2016	23
13	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer Molecular Cancer Therapeutics ·Sebastian Stintzing, Wu Zhang, Volker Heinemann, Daniel Neureiter, Ralf Kemmerling, Thomas Kirchner, Andreas Jung, Matthias Folwaczny, Dongyun Yang, Yan Ning, Ana Sebio, Stefan Stremitzer, Yu Sunakawa, Satoshi Matsusaka, Shinichi Yamauchi, Fotios Loupakis, Chiara Cremolini, Alfredo Falcone, Heinz‐Josef Lenz	2015	5
14	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients Annals of Oncology ·Bruno Vincenzi, Chiara Cremolini, Andrea Sartore‐Bianchi, Anna Russo, Francesco Mannavola, Giuseppe Perrone, Francesco Pantano, Fotios Loupakis, Daniele Rossini, Elena Ongaro, Erica Bonazzina, Alice Zoccoli, Giovanna De Maglio, Gabriella Fontanini, Alfredo Falcone, Daniele Santini, Andrea Onetti Muda, Salvatore Siena, Giuseppe Tonini, G. Aprile	2015	2
15	Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis Annals of Oncology ·Chiara Cremolini, Fotios Loupakis, Daniele Rossini, Gianluca Masi, Lisa Salvatore, C. Barbara, I. Brunetti, Carlotta Antoniotti, Cristina Granetto, Enrico Cortesi, S. Chiara, S. Vitello, Sara Lonardi, L. Ciuffreda, Giovanni Tomasello, Monica Ronzoni, Angela Buonadonna, Daniela Tomčíková, Luca Boni, Alfredo Falcone	2014	2
16	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States Molecular Cancer Therapeutics ·Takeru Wakatsuki, Melissa J. LaBonte, Pierre Bohanes, Wu Zhang, Dongyun Yang, Mizutomo Azuma, Afsaneh Barzi, Yan Ning, Fotios Loupakis, Siamak Saadat, Nico Volz, Sebastian Stintzing, Rita El‐Khoueiry, Wasaburo Koizumi, Masahiko Watanabe, Manish A. Shah, Justin Stebbing, Georgios Giamas, Heinz‐Josef Lenz	2013	18
17	Liquid biopsy: monitoring cancer-genetics in the blood Nature Reviews Clinical Oncology ·Emily Crowley, Federica Di Nicolantonio, Fotios Loupakis, Alberto Bardelli Hit paper breakdown →	2013	1374
18	Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. Annals of Oncology ·Lisa Salvatore, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Gianluca Masi, Carlotta Antoniotti, Lorenzo Fornaro, Elisa Sensi, Cristiana Lupi, Francesca Bergamo, Sara Lonardi, Zagonel, Gabriella Fontanini, Alfredo Falcone	2012	4
19	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan–cetuximab Annals of Oncology ·Mario Scartozzi, Riccardo Giampieri, Elena Maccaroni, Alessandra Mandolesi, Lucio Giustini, R. Silva, Alberto Zaniboni, Tommasina Biscotti, Simona Biagetti, Gennaro Galizia, Fotios Loupakis, Alfredo Falcone, Italo Bearzi, Stefano Cascinu	2011	35
20	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases Annals of Surgery ·Gianluca Masi, Fotios Loupakis, Luca Emanuele Pollina, Enrico Vasile, Samanta Cupini, Sergio Ricci, I. Brunetti, Roberta Ferraldeschi, Giuseppe Naso, Franco Filipponi, Andrea Pietrabissa, Orlando Goletti, Giacomo Giulio Baldi, Lorenzo Fornaro, M. Andreuccetti, Alfredo Falcone	2009	165

About Fotios Loupakis

Fotios Loupakis is a scholar working on Oncology, Hepatology, Cancer Research, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 315 papers that have together received 11.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (238 papers), Cancer Treatment and Pharmacology (84 papers), Gastric Cancer Management and Outcomes (67 papers), Hepatocellular Carcinoma Treatment and Prognosis (61 papers), Genetic factors in colorectal cancer (59 papers), Lung Cancer Treatments and Mutations (56 papers), Cancer Genomics and Diagnostics (44 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers). The work is most often cited by research in Oncology (8.3k citations), Hepatology (2.2k citations), Cancer Research (3.1k citations), Pathology and Forensic Medicine (2.9k citations) and Pulmonary and Respiratory Medicine (3.6k citations). Fotios Loupakis has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Alfredo Falcone, Federica Di Nicolantonio, Alberto Bardelli, Emily Crowley, Chiara Cremolini, Gianluca Masi, Lisa Salvatore, Giuseppe Tonini, Sara Lonardi and Heinz‐Josef Lenz. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Pharmacogenomics Journal, Clinical Colorectal Cancer and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact